Press release
Hope on the Horizon: DelveInsight's AL Amyloidosis Clinical Trials Report Reveals Major Advancements in AL Amyloidosis Treatment | Alexion, Prothena Biosciences Ltd, Millennium Pharmaceuticals Inc, GlaxoSmithKline, Boston Medical Center, Janssen, and othe
AL Amyloidosis Pipeline
In the AL Amyloidosis Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, AL Amyloidosis NDA approvals (if any), and product development activities comprising the technology, AL Amyloidosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
To explore more information on the latest breakthroughs in the AL Amyloidosis pipeline treatment landscape of the report, click here @ AL Amyloidosis Pipeline- https://www.delveinsight.com/report-store/al-amyloidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the AL Amyloidosis Pipeline Report
• DelveInsight's AL Amyloidosis Pipeline analysis depicts a robust space with 10+ active players working to develop 10+ pipeline treatment therapies.
• The leading AL Amyloidosis Companies working in the market include Alexion, Prothena Biosciences Ltd, Millennium Pharmaceuticals Inc, GlaxoSmithKline, Boston Medical Center, Janssen Pharmaceuticals, Cephalon, Celgene Corporation, Prothena Biosciences Ltd, Genentech Inc, Sanofi, Bristol-Myers Squibb, Takeda, Sorrento Therapeutics Inc, Amgen, Criterium Inc, and others.
• Promising AL Amyloidosis Pipeline Therapies in the various stages of development include CAEL-101, SoC: cyclophosphamide, bortezomib, and Dexamethasone (CyBorD), Daratumumab, Ixazomib, Cyclophosphamide, Belantamab mafodotin, Pomalidomide, and others.
• On May 2023, Alexion announced a study of phase 3 clinical trials for CAEL-101. The primary purpose of this study is to determine whether CAEL-101, a monoclonal antibody that removes AL amyloid deposits from tissues and organs, improves overall survival and it is safe and well tolerated in patients with stage IIIa AL amyloidosis.
• On February 2023, Life Molecular Imaging GmbH announced a study of phase 3 clincial trials for [18F] florbetaben. This is an open-label, multi-center pivotal Phase 3 study to visually and quantitatively assess PET images obtained after single application of 300 MBq [18F] florbetaben and PET scanning of patients with suspected cardiac amyloidosis.
• On March 2023, European Myeloma Network announced a study of phase 2 clinical trials for Belantamab mafodotin. This is an open-label, multicenter, Phase 2 study in subjects with previously treated patients with light chain (AL) amyloidosis in need for therapy.
AL Amyloidosis Overview
AL amyloidosis is the most common type, with approximately 4,500 new cases diagnosed every year. It usually affects people from ages 50-80, although there are a few cases of people being diagnosed as early as their late 20s. About two-thirds of the patients are male.
To explore more information on the latest breakthroughs in the AL Amyloidosis Pipeline treatment landscape of the report, click here @ https://www.delveinsight.com/sample-request/al-amyloidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
AL Amyloidosis Emerging Drugs Profile
• CAEL-101: Caelum Biosciences
• NXC-201: Nexcella, Inc.
AL Amyloidosis Pipeline Therapeutics Assessment
There are approx. 10+ key companies which are developing the therapies for AL Amyloidosis. The AL Amyloidosis companies which have their AL Amyloidosis drug candidates in the most advanced stage, i.e. phase III.
Request a sample and discover the recent advances in AL Amyloidosis Ongoing Clinical Trial Analysis and Medications, click here @ https://www.delveinsight.com/sample-request/al-amyloidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
AL Amyloidosis Drugs and Companies
• CAEL-101: Alexion
• Dexamethasone: Millennium Pharmaceuticals Inc
• Belantamab Mafodotin: GlaxoSmithKline
• Daratumumab: Janssen Pharmaceuticals
• Pomalidomide: Boston Medical Center
AL Amyloidosis Therapeutics Assessment
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Some of the Companies in the AL Amyloidosis Therapeutics Market include-
Alexion, Prothena Biosciences Ltd, Millennium Pharmaceuticals Inc, GlaxoSmithKline, Boston Medical Center, Janssen Pharmaceuticals, Cephalon, Celgene Corporation, Prothena Biosciences Ltd, Genentech Inc, Sanofi, Bristol-Myers Squibb, Takeda, Sorrento Therapeutics Inc, Amgen, Criterium Inc, and others.
Dive deep into rich insights for drugs for AL Amyloidosis Pipeline, click here for AL Amyloidosis Unmet Needs and Analyst Views @ https://www.delveinsight.com/sample-request/al-amyloidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the AL Amyloidosis Pipeline Report
• Coverage- Global
• AL Amyloidosis Companies- Alexion, Prothena Biosciences Ltd, Millennium Pharmaceuticals Inc, GlaxoSmithKline, Boston Medical Center, Janssen Pharmaceuticals, Cephalon, Celgene Corporation, Prothena Biosciences Ltd, Genentech Inc, Sanofi, Bristol-Myers Squibb, Takeda, Sorrento Therapeutics Inc, Amgen, Criterium Inc, and others.
• AL Amyloidosis Pipeline Therapies- CAEL-101, SoC: cyclophosphamide, bortezomib, and Dexamethasone (CyBorD), Daratumumab, Ixazomib, Cyclophosphamide, Belantamab mafodotin, Pomalidomide, and others
• AL Amyloidosis Segmentation: Product Type, Molecule Type, Route of Administration
Got Queries? Find out the related information on AL Amyloidosis Mergers and acquisitions, Licensing Activities @ https://www.delveinsight.com/sample-request/al-amyloidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. AL Amyloidosis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. AL Amyloidosis- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. CAEL-101: Caelum Biosciences
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Drug Name: Company Name
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. NXC-201: Nexcella, Inc.
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. LambdaMab 10B3 & 7F11: HaemaLogiX Ltd.
18. Drug profiles in the detailed report…..
19. Inactive Products
20. AL Amyloidosis Key Companies
21. AL Amyloidosis Key Products
22. AL Amyloidosis- Unmet Needs
23. AL Amyloidosis- Market Drivers and Barriers
24. AL Amyloidosis- Future Perspectives and Conclusion
25. AL Amyloidosis Analyst Views
26. AL Amyloidosis Key Companies
27. Appendix
List of Top Selling Market Research Reports in 2023
https://www.delveinsight.com/report-store/alcoholic-hepatitis-market
https://www.delveinsight.com/report-store/b-cell-maturation-antigen-targeted-therapies-market
https://www.delveinsight.com/report-store/blastomycosis-market
https://www.delveinsight.com/report-store/chronic-pulmonary-infections-due-to-pseudomonas-aeruginosa-in-patients-with-cystic-fibrosis-market
https://www.delveinsight.com/report-store/c-x-c-chemokine-receptor-inhibitors-competitive-landscape-market-and-pipeline-analysis
https://www.delveinsight.com/report-store/digestive-system-fistula-market
https://www.delveinsight.com/report-store/fertility-monitoring-devices-fertility-testing-devices-market
https://www.delveinsight.com/report-store/hay-fever-conjunctivitis-market
https://www.delveinsight.com/report-store/kawasaki-disease-market
https://www.delveinsight.com/report-store/myopia-progression-market
https://www.delveinsight.com/report-store/pecoma-market
https://www.delveinsight.com/report-store/pediatric-growth-hormone-deficiency-market
https://www.delveinsight.com/report-store/percutaneous-arterial-closure-device-market
https://www.delveinsight.com/report-store/vital-sign-monitors-external-remote-patient-monitoring-devices-market
https://www.delveinsight.com/report-store/upper-tract-urothelial-cancer-market
https://www.delveinsight.com/report-store/varicose-vein-treatment-devices-market
https://www.delveinsight.com/report-store/uk-healthcare-outlook-report
https://www.delveinsight.com/report-store/supraventricular-tachycardia-market
https://www.delveinsight.com/report-store/stem-cell-market
https://www.delveinsight.com/report-store/soft-tissue-defect-market
https://www.delveinsight.com/report-store/small-lymphocytic-lymphoma-market
https://www.delveinsight.com/report-store/shigella-infections-market
https://www.delveinsight.com/report-store/ranibizumab-biosimilars-insight
https://www.delveinsight.com/report-store/radiation-retinopathy-market
https://www.delveinsight.com/report-store/primary-biliary-cholongitis-pbc-market
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hope on the Horizon: DelveInsight's AL Amyloidosis Clinical Trials Report Reveals Major Advancements in AL Amyloidosis Treatment | Alexion, Prothena Biosciences Ltd, Millennium Pharmaceuticals Inc, GlaxoSmithKline, Boston Medical Center, Janssen, and othe here
News-ID: 3142681 • Views: …
More Releases from DelveInsight Business Research
Gastric Cancer Market to Exceed USD 700 Million in HER2+ Segment by 2034 Across …
Gastric cancer is the fifth most common malignancy worldwide, with incidence varying by region and highest rates reported in Eastern Asia and Eastern Europe. Japan records the highest burden among the 7MM, with about 129,500 cases in 2024. Many patients, particularly in Western countries, are diagnosed at advanced (Stage IV) stages, while Japan detects more cases early (Stage I). In the US, around 35% present with metastatic disease at diagnosis,…
Myelofibrosis Market to Double by 2034, Surpassing USD 5.6 Billion Across 7MM wi …
The Myelofibrosis market across the seven major markets (7MM) is anticipated to experience significant growth, rising from approximately USD 2,602 million in 2025 to nearly USD 5,638 million by 2034, reflecting a compound annual growth rate (CAGR) of about 9% during the forecast period.
In 2024, the market was valued at around USD 2.2 billion, with the United States leading at nearly USD 1.7 billion, far surpassing the EU4, the United…
Triple-Negative Breast Cancer Clinical Trial Landscape Expands With 170+ Pipelin …
An expanding portfolio of novel therapies for triple-negative breast cancer (TNBC) including TECENTRIQ (Hoffmann-La Roche), IPI-549 (Infinity Pharmaceuticals), Leronlimab (CytoDyn), MDNA11 (Medicenna Therapeutics), VIP236 (Vincerx Pharma), and CFI-400945 (Treadwell Therapeutics) is anticipated to significantly influence market expansion and transform the TNBC treatment landscape.
DelveInsight's Triple Negative Breast Cancer Pipeline Insight report offers an extensive evaluation of more than 165 companies and over 170 therapeutic candidates advancing through the TNBC pipeline. The…
Asthma Market to Witness Steady Growth Through 2034 Driven by Novel Biologics an …
DelveInsight's latest Asthma Market Insights, Epidemiology, and Market Forecast - 2034 report provides an in-depth evaluation of current treatment practices, emerging asthma drugs, market share of individual therapies, and forecasted market trends across the seven major markets (7MM) - the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
The asthma market is expected to experience sustained growth over the next decade, supported by the launch of…
More Releases for Amyloidosis
Amyloidosis Market Massive Growth opportunity Ahead
Introduction
Amyloidosis is a rare, progressive disease characterized by the abnormal deposition of amyloid proteins in tissues and organs, leading to organ dysfunction and, in severe cases, life-threatening complications. The condition can affect the kidneys, heart, liver, and nervous system, making early detection and effective treatment essential. Historically underdiagnosed, amyloidosis is now gaining visibility due to advances in diagnostic tools, imaging technologies, and therapeutic innovations.
In 2024, the global Amyloidosis Market is…
Evolving Market Trends In The Transthyretin Amyloidosis Treatment Industry: Inno …
The Transthyretin Amyloidosis Treatment Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Transthyretin Amyloidosis Treatment Market Size During the Forecast Period?
The market for transthyretin amyloidosis treatments has witnessed significant growth in the past few years. The market, which was valued at…
What's Driving the Transthyretin Amyloidosis Treatment Market 2025-2034: Increas …
What Are the Projections for the Size and Growth Rate of the Transthyretin Amyloidosis Treatment Market?
The market for transthyretin amyloidosis treatment has seen robust growth in the past years. Its size is forecasted to increase from $5.52 billion in 2024 to $5.95 billion in 2025, with a compound annual growth rate (CAGR) of 7.8%. The surge in the market over the historic period is due to increased disease awareness, progress…
Unveiling Transthyretin Amyloidosis Treatment Market 2024
The transthyretin amyloidosis treatment market size has grown strongly in recent years. It will grow from $5.07 billion in 2023 to $5.52 billion in 2024 at a compound annual growth rate (CAGR) of 8.9%. The growth in the historic period can be attributed to increased disease awareness, advancements in diagnostic tools, drug development and approvals, patient advocacy and support, collaboration in research..
The transthyretin amyloidosis treatment market size is…
AL Amyloidosis Therapeutics Market - Transforming the landscape of AL amyloidosi …
Newark, New Castle, USA: The "AL Amyloidosis Therapeutics Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
AL Amyloidosis Therapeutics Market: https://www.growthplusreports.com/report/al-amyloidosis-therapeutics-market/8684
This latest report researches the industry structure,…
Transthyretin Amyloidosis (ATTR) Market 2022 | Detailed Report
The top-notch information research report published by markets and markets is a vital asset that offers qualitative and quantitative factors of the Transthyretin Amyloidosis (ATTR) market. The research study and methodologies mentioned in the report examine the critical vendors by considering their contribution to the global market. Furthermore, the report offers an in-depth insight into leading players’ performance based on revenue generation and client requirements. Also, the research report reveals…
